scholarly article | Q13442814 |
P356 | DOI | 10.1227/01.NEU.0000338067.83059.EB |
P698 | PubMed publication ID | 19240603 |
P50 | author | Masato Naraoka | Q42362440 |
P2093 | author name string | Norihito Shimamura | |
Hiroki Ohkuma | |||
Takahiro Nakano | |||
Akira Munakata | |||
Kenichirou Asano | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | edaravone | Q335099 |
P304 | page(s) | 423-8; discussion 428-9 | |
P577 | publication date | 2009-03-01 | |
P1433 | published in | Neurosurgery | Q7002693 |
P1476 | title | Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage | |
P478 | volume | 64 |
Q35088321 | A proposed definition of symptomatic vasospasm based on treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan: Consensus 2009, a project of the 25 Spasm Symposium |
Q48308572 | Advances in Treatment of Cerebral Vasospasm: an Update |
Q43262774 | Alpha lipoic acid alleviates oxidative stress and preserves blood brain permeability in rats with subarachnoid hemorrhage |
Q36711857 | Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future |
Q48234772 | Edaravone attenuates intracerebroventricular streptozotocin-induced cognitive impairment in rats. |
Q92308846 | Edaravone combined with cinepazide maleate on neurocyte autophagy and neurological function in rats with subarachnoid hemorrhage |
Q27335848 | Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease |
Q40898682 | Edaravone offers neuroprotection for acute diabetic stroke patients |
Q47376779 | Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus |
Q93170488 | Effect of L-Arginine Therapy on Vasospasm: Experimental Study in Rats |
Q34456056 | Effect of edaravone on radiation-induced brain necrosis in patients with nasopharyngeal carcinoma after radiotherapy: a randomized controlled trial |
Q91762699 | Effect of treatment modality and cerebral vasospasm agent on patient outcomes after aneurysmal subarachnoid hemorrhage in the elderly aged 75 years and older |
Q26748764 | Intracerebral Hemorrhage, Oxidative Stress, and Antioxidant Therapy |
Q36831190 | Medical Management of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage: A Review of Current and Emerging Therapeutic Interventions |
Q34504672 | Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury |
Q40050004 | Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis |
Q38170048 | Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage |
Q43079903 | Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. |
Q39663927 | Statins and anti-inflammatory therapies for subarachnoid hemorrhage. |
Q38213375 | The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage. |
Q58920601 | Therapeutic time window for edaravone treatment of traumatic brain injury in mice |
Q33747387 | To look beyond vasospasm in aneurysmal subarachnoid haemorrhage. |
Q36230958 | Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis |
Q34095042 | Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature |
Search more.